Who
RA CAPITAL MANAGEMENT, L.P.
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, Wave Life Sciences; Director and 10% owner, Vor Biopharma; Director and 10% owner, Climb Bio; Director and 10% owner, Sionna Therapeutics; Director and 10% owner, Tyra Biosciences; Director and 10% owner, Artiva Biotherapeutics; Director and 10% owner, Septerna; 10% owner, Inhibikase Therapeutics.
In numbers
- Trades disclosed
- 491
- Buys
- 105
- Sells
- 50
- Bought
- $1.4B
- Sold
- $295.6M
- Companies
- 54
- Companies where not an officer
- 54
- First trade
- 6 Jun 2008
- Last trade
- 5 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 7 Oct 2026 | WVE Wave Life SciencesBiotechnology | SEC FORM 4 Code A | —10,700 at $0.00 | filing |
| 5 Oct 2026filed 7 Oct 2026 | WVE Wave Life Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,000 at $0.00 | filing |
| 2 Oct 2026filed 5 Oct 2026 | VOR Vor BiopharmaBiotechnology | SEC FORM 4 Code M | $6,400500 at $12.80 | filing |
| 2 Oct 2026filed 5 Oct 2026 | VOR Vor Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —500 at $0.00 | filing |
| 28 Sep 2026filed 30 Sep 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Code M | $35K10,000 at $3.46 | filing |
| 28 Sep 2026filed 30 Sep 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Code M | $30K10,000 at $3.00 | filing |
| 28 Sep 2026filed 30 Sep 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Code M | $79K10,000 at $7.89 | filing |
| 28 Sep 2026filed 30 Sep 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Code M | $52K40,000 at $1.29 | filing |
| 28 Sep 2026filed 30 Sep 2026 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 28 Sep 2026filed 30 Sep 2026 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 28 Sep 2026filed 30 Sep 2026 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 28 Sep 2026filed 30 Sep 2026 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | SION Sionna TherapeuticsBiotechnology | SEC FORM 4 Sold | $21.6M3,415,011 at $6.32 | filing |
| 17 Sep 2026filed 21 Sep 2026 | SION Sionna TherapeuticsBiotechnology | SEC FORM 4 Sold | $252K33,800 at $7.46 | filing |
| 17 Sep 2026filed 21 Sep 2026 | SION Sionna TherapeuticsBiotechnology | SEC FORM 4 Sold | $21.6M3,415,011 at $6.32 | filing |
| 17 Sep 2026filed 21 Sep 2026 | SION Sionna TherapeuticsBiotechnology | SEC FORM 4 Sold | $252K33,800 at $7.46 | filing |
| 15 Sep 2026filed 17 Sep 2026 | TYRA Tyra Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | $200.0M9,078,529 at $22.03 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,250 at $0.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,750 at $0.00 | filing |
| 24 Aug 2026filed 26 Aug 2026 | VOR Vor BiopharmaBiotechnology | SEC FORM 4 Code M | $5,6041,500 at $3.74 | filing |
News
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid TumorsPBLS · manilatimes.net · 24 Oct 2026Parabilis Medicines Shares Rise 13% On Plans To Present Updated Zolucatetide Desmoid Tumor DataPBLS · rttnews.com · 19 Oct 2026Parabilis Medicines (NASDAQ:PBLS) Shares Up 4.9% – Here's What HappenedPBLS · themarketsdaily.com · 19 Oct 2026Vor Biopharma (NASDAQ:VOR) Stock Rating Upgraded by CitigroupVOR · tickerreport.com · 17 Oct 2026Vor Biopharma (NASDAQ:VOR) Shares Up 7.2% on Analyst UpgradeVOR · tickerreport.com · 17 Oct 2026Hemab Therapeutics (NASDAQ:COAG) Stock Rating Upgraded by Rodman & RenshawCOAG · dailypolitical.com · 14 Oct 2026
0 headlines in the last 90 days name RA CAPITAL MANAGEMENT, L.P.; 6 articles from the last 14 days about the 6 companies they traded most, at most three about any one of them.